NCT05400226View on ClinicalTrials.gov

Phase 2 Study of VGT-309 in Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

May 24, 2022

Primary Completion Date

June 24, 2023

Study Completion Date

December 15, 2023

Conditions
Lung Cancer
Interventions
DRUG

VGT-309

VGT-309 is an tumor-targeted, activatable fluorescent imaging agent which will be used with near infrared imaging during surgery to identify tumor.

Trial Locations (1)

19104

Hospital of the University of Pennsylvania, Philadelphia

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Vergent Bioscience, Inc.

INDUSTRY